ANAnanth U. Nayak

Ananth U. Nayak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ananth U. Nayak has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Lakshminarayanan Varadhan

    University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, North Staffordshire, UK

    3 shared publications
  • Alan Michael Nevill

    Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, UK

    2 shared publications
  • Baldev M. Singh

    Wolverhampton Diabetes Centre, New Cross Hospital, Wolverhampton, U.K.

    2 shared publications
  • George I Varughese

    Department of Diabetes, Endocrinology and General Medicine, University Hospital of North Midlands NHS Trust, Stoke on Trent, UK

    2 shared publications
  • Sushuma Kalidindi

    Combined Antenatal Diabetes Clinic, University Hospital of North Midlands NHS Trust, Stoke on Trent ST4 6QG, Staffordshire, United Kingdom

    2 shared publications
  • Arjun Mukherjee

    Department of Diabetes and Endocrinology University Hospitals of North Staffordshire NHS Trust Stoke on Trent UK

    1 shared publication

Latest Publications

  • Open Access

    Association of hypoglycaemia in screening oral glucose tolerance test in pregnancy with low birth weight fetus

    by Ananth U Nayak, Arun M A Vijay, Radha Indusekhar, Sushuma Kalidindi, Venkata M Katreddy, Lakshminarayanan Varadhan

    Association of hypoglycaemia in screening oral glucose tolerance test in pregnancy with low birth weight fetus


  • Open Access

    Course of Diabetic retinopathy following bariatric surgery in patients with Type 2 diabetes: the immediate and late impact of glycaemic control

    by Lakshminarayanan Varadhan, Sushuma Kalidindi, Gurmit Gill, Hafsa Imran, Tracy Humphreys, George I Varughese, Ananth U Nayak

    OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.

  • An Audit on Fixed dose (555 MBq) Radioactive-iodine for Hyperthyroidism at a University Hospital

    by Arun Muthukaruppan Alagar Vijay, Julie Cooper, Lakshminarayanan Varadhan, Ananth U Nayak

    Background/Aim: Radioactive-iodine (RAI) therapy aims to cure hyperthyroidism, with some International authorities recommending a sufficient RAI dose to render patients hypothyroid. An audit on low dose RAI (n=69). Thyroid status at 6 weeks, 3–6 months and 12 months was determined to analyse the rates of relapse and Hypothyroidism post RAI. Results: Demographics of cohort: Age 54.5±13.8 (mean±S.D.) years; Caucasians 90%; Females 78%; Graves’ disease 70%; Pre-existing TED 10%. RAI was used as primary treatment in 5.8% and others post ATD treatment with mean duration 13.6 months. Mean duration of thyrotoxicosis 45.2±41.1 months. The proportion with relapse of Thyrotoxicosis and those who developed hypothyroidism at 6 months were 15.5 and 55.2% respectively. On retrospective analysis, among patients who were thyrotoxic at 6 months (15.5% of n=58 with 6 months data), their status at 6 weeks post RAI review were: Euthyroid 22.2%, Hypothyroid 0%, Subclinical Hypothyroid 0%, Subclinical Thyrotoxic 11.1% and Thyrotoxic 66.7%. Of patients who were thyrotoxic at 12 months (8.3% of n=36 with 12 months data), 100% were Thyrotoxic at 6 months post RAI. On logistic regression neither demographics nor biochemical parameters predicted Thyrotoxicosis relapse at 6 or 12 months post RAI. Conclusion: Standardisation of RAI dose to 555 MBq for treatment of hyperthyroidism improved cure rates of hyperthyroidism, reducing the risk of relapse of thyrotoxicosis and with higher hypothyroidism rates. The incidence of transient Eu/Hypothyroid state post RAI progressing to overt Thyrotoxicosis was low with 555 MBq.

  • Open Access

    Thymic hyperplasia and its spontaneous resolution with treatment of Graves' hyperthyroidism

    by Monisha Shanmugasundaram, Laks Varadhan, Mahesh V R Katreddy, Ananth U Nayak


  • Open Access

    Splenic abscess as a potential initial manifestation of quiescent infective endocarditis in a patient with bronchopneumonia

    by Lindsay McOwat, Kah Fai Wong, George I Varughese, Ananth U Nayak

    A 78-year-old woman presented to the acute medical unit with a productive cough, dyspnoea and decreased appetite of 4 days duration. Initial assessment supported a diagnosis of right-sided community-acquired pneumonia and she was started on antibiotics. In view of the clinical finding of splenomegaly, she had an ultrasound and, subsequently, a CT of the abdomen, which revealed a large splenic abscess. Pending cultures from a sample obtained from percutaneous drainage of the abscess, she was started on intravenous meropenem. The initial echocardiogram did not suggest any evidence of endocarditis. The pus drained from the abscess on cultures was subsequently positive forStaphylococcus aureus. An MRI of the spine excluded discitis as a source of infection. Owing to a high index of clinical suspicion a repeat echocardiogram was undertaken after 1-week, which confirmed acute endocarditis. The patient was treated with intravenous antibiotics for 6 weeks with improvement in clinical, radiological and biochemical parameters.


  • Can a baseline morning cortisol predict outcome of short Synacthen test in an endocrine unit in an outpatient setting

    by Lakshminarayanan Varadhan, Ananth U. Nayak, Arjun Mukherjee, Biju Jose, George I. Varughese


  • Open Access

    Association of Glycation Gap With Mortality and Vascular Complications in Diabetes

    by Ananth U. Nayak, Alan M. Nevill, Paul Bassett, Baldev M. Singh

    OBJECTIVE: The “glycation gap” (G-gap), an essentially unproven concept, is an empiric measure of disagreement between HbA1c and fructosamine, the two indirect estimates of glycemic control. Its association with demographic features and key clinical outcomes in individuals with diabetes is uncertain. RESEARCH DESIGN AND METHODS: The G-gap was calculated as the difference between measured HbA1c and a fructosamine-derived standardized predicted HbA1c in 3,182 individuals with diabetes. The G-gap’s associations with demographics and clinical outcomes (retinopathy, nephropathy, macrovascular disease, and mortality) were determined. RESULTS: Demographics varied significantly with G-gap for age, sex, ethnic status, smoking status, type and duration of diabetes, insulin use, and obesity. A positive G-gap was associated with retinopathy (odds ratio 1.24 [95% CI 1.01–1.52], P = 0.039), nephropathy (1.55 [1.23–1.95], P < 0.001), and, in a subset, macrovascular disease (1.91 [1.18–3.09], P = 0.008). In Cox regression analysis, the G-gap had a “U”-shaped quadratic relationship with mortality, with both negative G-gap (1.96 [1.50–2.55], P < 0.001) and positive G-gap (2.02 [1.57–2.60], P < 0.001) being associated with a significantly higher mortality. CONCLUSIONS: We confirm published associations of G-gap with retinopathy and nephropathy. We newly demonstrate a relationship with macrovascular and mortality outcomes and potential links to distinct subpopulations of diabetes.


    • 14 June 2013
      • Vol. 126  (1376) , 97-8

    Medical image. Pneumomediastinum--an unusual complication of diabetic ketoacidosis.

    by Venkata M R Katreddy, George I Varughese, Ananth U Nayak

  • Open Access

    Evidence for Consistency of the Glycation Gap in Diabetes

    by Ananth U. Nayak, Martin R. Holland, David R. Macdonald, Alan Nevill, Baldev M. Singh

    OBJECTIVE: Discordance between HbA1c and fructosamine estimations in the assessment of glycemia is often encountered. A number of mechanisms might explain such discordance, but whether it is consistent is uncertain. This study aims to coanalyze paired glycosylated hemoglobin (HbA1c)-fructosamine estimations by using fructosamine to determine a predicted HbA1c, to calculate a glycation gap (G-gap) and to determine whether the G-gap is consistent over time. RESEARCH DESIGN AND METHODS: We included 2,263 individuals with diabetes who had at least two paired HbA1c-fructosamine estimations that were separated by 10 ± 8 months. Of these, 1,217 individuals had a third pair. The G-gap was calculated as G-gap = HbA1c minus the standardized fructosamine-derived HbA1c equivalent (FHbA1c). The hypothesis that the G-gap would remain consistent in individuals over time was tested. RESULTS: The G-gaps were similar in the first, second, and third paired samples (0.0 ± 1.2, 0.0 ± 1.3, and 0.0 ± 1.3, respectively). Despite significant changes in the HbA1c and fructosamine, the G-gap did not differ in absolute or relative terms and showed no significant within-subject variability. The direction of the G-gap remained consistent. CONCLUSIONS: The G-gap appears consistent over time; thus, by inference any key underlying mechanisms are likely to be consistent. G-gap calculation may be a method of exploring and evaluating any such underlying mechanisms.


  • Open Access

    Exenatide therapy in insulin-treated type 2 diabetes and obesity

    by U. A. Nayak, J. Govindan, V. Baskar, D. Kalupahana, B. M. Singh

    Background: Exenatide, a GLP-1 analogue, is used in combination with oral anti-diabetic agents in type 2 diabetes and obesity, and promotes weight loss. Exenatide use in combination with insulin in insulin-treated type 2 diabetes and obesity is unlicensed in the UK and outcomes are unclear. Aims: To assess the effectiveness of exenatide in insulin-treated type 2 diabetes with obesity. Design and Methods: This prospective study included 174 consecutive patients with insulin-treated type 2 diabetes and obesity initiated on exenatide in our out-patient, between October 2007 and November 2008. Weight, BMI, HbA1c, serum fructosamine, total cholesterol, HDL-cholesterol and insulin doses were recorded at baseline, 3, 6 and 12 months. Side effect profiles were recorded. Results: Fourteen patients discontinued exenatide before 3 months of initiation, because of side effects, and were excluded. Data were analysed on remaining 160 people all of whom completed 6 months and 57 completed 12 months treatment. Mean weight loss was 10.7 ± 5.7 kg and 12.8 ± 7.5 kg (P < 0.001) at 6 and 12 months. Insulin doses dropped significantly (mean 144 ± 90 U/day at baseline to 51 ± 55 U/day and 55 ± 53 U/day at 6 and 12 months). At 3 months, 25% came off insulin. There was little change in HbA1c. Conclusions: Exenatide therapy in insulin-treated type 2 diabetes and obesity was associated with very significant reductions in weight and insulin doses. Exenatide should be considered in people with type 2 diabetes on insulin and have obesity, weight gain and poor glycaemic control.